Thymosin Alpha-1 Dosage Guide: Immune Peptide Reconstitution & Research Protocol

Thymosin Alpha-1 research guide: immune modulation mechanism, 1.6 mg dosing protocol, reconstitution math, and syringe calculator for subcutaneous administration.

TL;DR — Thymosin Alpha-1 at a Glance

• Thymosin Alpha-1 (TA-1) is a 28-amino acid peptide derived from thymosin fraction 5, the principal immune-regulating secretion of the thymus gland
• Approved as Zadaxin in over 35 countries for treatment of hepatitis B, hepatitis C, and as a vaccine adjuvant and cancer immunotherapy
• Clinical standard dose is 1.6 mg subcutaneous, twice per week — one of the most precisely characterized dosing regimens in peptide research
• Promotes T-cell maturation, dendritic cell activation, and NK cell function through multiple converging immune pathways
• Calculate your Thymosin Alpha-1 reconstitution now →

⚠️ Research Disclaimer: Thymosin Alpha-1 is a research compound not approved by the FDA for human use in the United States, though it holds regulatory approval in numerous other countries. All information is for educational purposes only and does not constitute medical advice.

Thymosin Alpha-1 peptide occupies a genuinely unique position in the peptide research landscape: unlike the vast majority of research peptides, which have limited or no formal clinical approval anywhere in the world, TA-1 is a fully approved pharmaceutical product in over 35 countries, marketed under the brand name Zadaxin by SciClone Pharmaceuticals. This regulatory status means that Thymosin Alpha-1 research is supported by an extensive body of controlled clinical trial data — phase II and phase III trials in hepatitis B, hepatitis C, non-small cell lung cancer, and vaccine adjuvancy — that most research peptides simply do not have. Researchers studying immunomodulation, T-cell biology, or antiviral immune responses have access to an unusually robust evidence base.

At the molecular level, Thymosin Alpha-1 is a 28-amino acid peptide derived from prothymosin alpha, a larger protein originally isolated from calf thymus tissue by Allan Goldstein's group at George Washington University in the 1970s. The thymus gland, which is primarily active in early life and undergoes involution with age, is responsible for the maturation of T-lymphocytes from bone marrow precursors. TA-1 represents the biologically active core of thymosin fraction 5 — the peptide fraction responsible for the thymus's T-cell education function. Its administration effectively restores or augments thymic signaling in subjects with impaired T-cell immunity, making it a compelling research tool for immunology, oncology, and infectious disease applications. As a thymus-derived peptide with documented effects on immune aging, TA-1 also appears in longevity-focused peptide research.

How Thymosin Alpha-1 Modulates the Immune System: Mechanisms of Action

Thymosin Alpha-1 exerts its immunomodulatory effects through multiple converging pathways. At the cellular level, it acts primarily on immature T-lymphocytes, promoting their differentiation and maturation into functional T helper (CD4+) and cytotoxic T (CD8+) cells. This differentiation-promoting activity mirrors the natural thymic function and is mediated in part through the upregulation of surface expression of T-cell-specific markers including CD3 and CD4, allowing previously immature or functionally suppressed T-cells to re-enter the functional immune repertoire.

Beyond T-cell maturation, TA-1 has been shown to activate dendritic cells (DCs) — the antigen-presenting cells critical for initiating adaptive immune responses. Research published by Romani et al. (2012, Blood) demonstrated that TA-1 directly stimulates plasmacytoid dendritic cells to produce interferon-alpha (IFN-α), a key antiviral cytokine, while also promoting the maturation of myeloid DCs into fully functional antigen-presenting cells capable of priming naïve T-cell responses. This DC activation mechanism is one reason TA-1 has proven effective as a vaccine adjuvant in clinical trials — it essentially improves the immune system's ability to learn from and respond to antigenic challenge.

Natural killer (NK) cell activation represents a third mechanism. NK cells are innate immune effectors capable of destroying virally infected and tumor cells without prior sensitization. TA-1 upregulates NK cell cytotoxicity and promotes their expansion, contributing to both antiviral and anti-tumor defense. The combination of T-cell maturation + DC activation + NK cell upregulation gives Thymosin Alpha-1 a broad-spectrum immunostimulatory profile that distinguishes it from more narrowly targeted immune compounds like LL-37, which acts primarily through toll-like receptor pathways and direct antimicrobial activity.

Clinical Evidence and Approved Uses of Thymosin Alpha-1 (Zadaxin)

Thymosin Alpha-1's regulatory approvals are backed by a substantial clinical evidence base. In hepatitis B, a pivotal trial by Chien et al. demonstrated that TA-1 administration at 1.6 mg twice weekly for six months produced statistically significant improvements in HBeAg seroconversion and HBV DNA clearance compared to control, with a favorable safety profile. In chronic hepatitis C, multiple trials have evaluated TA-1 alone and in combination with interferon-alpha, with the combination showing improved sustained virologic response (SVR) rates compared to interferon monotherapy.

In oncology, TA-1 has been studied as an immunotherapy adjuvant in non-small cell lung cancer (NSCLC), melanoma, and hepatocellular carcinoma. A phase II trial by Schulof et al. demonstrated that TA-1 restored T-cell immune function in cancer patients with depressed cell-mediated immunity — an important finding given that T-cell exhaustion is a major barrier to effective anti-tumor immune responses. The compound is approved in several countries as an adjuvant for certain chemotherapy regimens and as a treatment to restore immune function in immunocompromised patients.

Vaccine adjuvancy is an emerging application: several studies have demonstrated that co-administration of TA-1 with influenza, hepatitis B, and COVID-19 vaccines produces improved seroconversion rates and higher antibody titers compared to vaccine alone, particularly in older adults and immunocompromised subjects where vaccine response is typically attenuated. This body of clinical trial data is simply unmatched by most other peptides available for research.

Thymosin Alpha-1 Dosage Protocols and Reconstitution Tables

The clinical standard dose for Thymosin Alpha-1, derived directly from the Zadaxin approval studies, is 1.6 mg administered subcutaneously twice per week. This dosing regimen has been used in virtually all phase II and phase III clinical trials and represents the most thoroughly characterized TA-1 dosing protocol. Some research contexts use daily dosing for shorter periods (for example, 1 mg/day for 10–14 days as an acute immunostimulatory protocol), but the twice-weekly 1.6 mg schedule remains the reference standard.

TA-1 is available for research in vial sizes of 1.6 mg (matching the clinical single-dose unit) and sometimes in 5 mg or 10 mg vials. Reconstitution is straightforward — TA-1 is stable in standard bacteriostatic water (BAC water), unlike IGF-1 variants that require acetic acid. The following table covers standard reconstitution scenarios:

Calculate your Thymosin Alpha-1 dose → Reconstitution Calculator

The most practical reconstitution for a 1.6 mg vial is 1.0 mL BAC water, yielding 1,600 mcg/mL (1.6 mg/mL), where the full 1.6 mg dose = exactly 100 units on a U-100 syringe = 1.0 mL. This clean correspondence between the clinical dose and a round syringe unit count simplifies dosing in research contexts considerably. Use the peptide reconstitution calculator to calculate for other vial sizes or custom concentrations.

Thymosin Alpha-1 vs LL-37 and VIP: Comparing Immune Peptides

Thymosin Alpha-1 is one of several peptides studied for immune modulation, and comparing it to LL-37 and VIP (vasoactive intestinal peptide) illustrates the different dimensions of immune research these compounds enable.

The key distinction is that TA-1 is primarily an adaptive immune upregulator — it improves the quality and quantity of T-cell responses, making the adaptive immune system more effective. LL-37 is primarily an innate immune activator and direct antimicrobial. VIP is immunosuppressive in many contexts, making it relevant for autoimmune and inflammatory research rather than immune upregulation. Researchers studying chronic immune suppression, viral clearance, or cancer immunosurveillance will find TA-1 most directly relevant. The immune peptides research guide provides a broader survey of the immune peptide research landscape.

Thymosin Alpha-1 Stability, Storage, and Research Protocol Design

Reconstituted Thymosin Alpha-1 is stable under standard peptide storage conditions: refrigerated at 2–8°C, protected from light, and used within 28–30 days. Lyophilized (freeze-dried) TA-1 is highly stable at room temperature and is not as sensitive to brief temperature excursions as some other research peptides. Long-term storage of lyophilized vials is best at -20°C or below. For a comprehensive overview of storage best practices across peptide classes, see the peptide storage guide.

For research protocols based on the clinical twice-weekly dosing standard, a 10 mg vial reconstituted to 1,000 mcg/mL provides enough solution for approximately 6 doses (6 × 1.6 mg = 9.6 mg), fitting neatly into a 3-week sub-protocol. This allows multi-week protocols to be planned around vial consumption with minimal leftover. If using 1.6 mg single-dose vials, reconstitute each vial fresh for each injection to maximize stability, though this is more resource-intensive. The BPC-157 complete research guide discusses similar storage and protocol planning considerations for another immune-relevant compound.

How to Calculate Thymosin Alpha-1 Doses Using Our Free Peptide Calculator

The peptide reconstitution calculator makes TA-1 dose calculation straightforward regardless of vial size. Enter the vial mass (e.g., 1.6 mg or 10 mg), the BAC water volume you plan to add, and your target dose (1.6 mg for the clinical standard). The calculator converts to concentration, then to syringe units. For researchers new to calculating milligram-level doses (TA-1 is dosed in mg, not mcg like many GH-axis peptides), the dosage calculator also provides unit conversion guidance and protocol scheduling support.

Frequently Asked Questions About Thymosin Alpha-1

Q: What is Thymosin Alpha-1 used for in research and clinical settings? A: In countries where Zadaxin is approved, Thymosin Alpha-1 is used clinically for the treatment of chronic hepatitis B, as an adjunct therapy in hepatitis C (in combination with interferon-alpha), and as a vaccine adjuvant to improve immunogenicity in immunocompromised patients. In research settings, it is studied for its T-cell maturation effects, NK cell activation, dendritic cell stimulation, cancer immunotherapy adjuvancy, and as a model compound for understanding thymus-mediated immune regulation. Its established clinical approval status makes it one of the better-characterized research peptides available.

Q: What countries is Thymosin Alpha-1 (Zadaxin) approved in? A: Thymosin Alpha-1 is approved under the Zadaxin brand name in over 35 countries, primarily across Asia, Eastern Europe, South America, and the Middle East. This includes China, Italy, the Philippines, Thailand, and numerous others. It does not hold FDA approval in the United States or EMA approval in the European Union for standard indications, though it has been used under compassionate use protocols in those jurisdictions.

Q: What is the standard Thymosin Alpha-1 research dose? A: The clinical standard and most frequently used research dose is 1.6 mg administered subcutaneously twice per week. This dose and schedule were used in the pivotal clinical trials for Zadaxin and represent the best-characterized dosing protocol. Some research protocols use daily dosing at 1.0 mg for acute immunostimulatory applications, but the twice-weekly 1.6 mg schedule remains the reference protocol for most research designs.

Q: How do you reconstitute Thymosin Alpha-1 for research? A: Thymosin Alpha-1 reconstitutes well in standard bacteriostatic water (BAC water). For a 1.6 mg vial, adding 1.0 mL BAC water yields a concentration of 1,600 mcg/mL (1.6 mg/mL), where the full 1.6 mg clinical dose corresponds exactly to 100 units on a U-100 syringe — a convenient correspondence that simplifies dosing. For larger vials (5 mg or 10 mg), add proportionally more BAC water to achieve 1,000 mcg/mL. Store reconstituted vials at 2–8°C and use within 28 days.

Q: How does Thymosin Alpha-1 differ from LL-37 as an immune peptide? A: Thymosin Alpha-1 and LL-37 operate through fundamentally different mechanisms. TA-1 modulates the adaptive immune system — specifically promoting T-cell maturation, dendritic cell activation, and NK cell function. It is an immune upregulator that improves the quality of antigen-specific immune responses. LL-37 is a cathelicidin antimicrobial peptide that primarily activates innate immune pathways through toll-like receptor signaling and directly disrupts microbial cell membranes. TA-1 is the appropriate choice for research focused on T-cell biology and adaptive immunity; LL-37 is more relevant for innate defense and antimicrobial mechanisms.

All content is for educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions